KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Operating Expenses for 15 consecutive years, with $215.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 41.08% to $215.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $781.2 million through Dec 2025, up 34.66% year-over-year, with the annual reading at $781.2 million for FY2025, 34.66% up from the prior year.
  • Operating Expenses for Q4 2025 was $215.5 million at Supernus Pharmaceuticals, down from $252.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $252.3 million in Q3 2025, with the low at $107.2 million in Q2 2021.
  • Average Operating Expenses over 5 years is $154.5 million, with a median of $151.6 million recorded in 2022.
  • The sharpest move saw Operating Expenses dropped 18.52% in 2023, then soared 87.13% in 2025.
  • Over 5 years, Operating Expenses stood at $153.0 million in 2021, then fell by 13.05% to $133.0 million in 2022, then grew by 24.3% to $165.3 million in 2023, then decreased by 7.6% to $152.8 million in 2024, then skyrocketed by 41.08% to $215.5 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $215.5 million, $252.3 million, and $153.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.